tranexamic acid has been researched along with Sarcoma in 6 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Sarcoma: A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tranexamic acid (TXA) is poorly studied in patients with bone and musculoskeletal sarcoma due to perceived increased risk of venous thromboembolism (VTE)." | 8.31 | Intravenous tranexamic acid decreases intraoperative transfusion requirements and does not increase incidence of symptomatic venous thromboembolic events in musculoskeletal sarcoma surgery. ( Andrews, NA; Crowley, B; Hess, MC; Howie, C; McGwin, G; Siegel, H; Singh, NP, 2023) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug that has been shown to reduce blood loss following surgery." | 5.91 | Intravenous tranexamic acid is associated with an increased risk of pulmonary embolism following sarcoma resection. ( Foster, D; Garner, H; Goulding, K; Houdek, M; Sebro, R; Spaulding, AC; Stanborough, R; Wilke, B, 2023) |
| "The aim of the present study was to assess the incidence of and risk factors for thromboembolic events-including assessment of the intraoperative use of tranexamic acid and postoperative use of chemical thromboprophylaxis-in patients undergoing operative treatment of primary bone or soft-tissue sarcoma or oligometastatic bone disease." | 5.69 | Incidence of and Risk Factors for Thromboembolism After Endoprosthetic Reconstruction in Musculoskeletal Oncology Patients. ( Forsberg, JA; Levin, AS; LiBrizzi, CL; Morris, CD; Sabharwal, S, 2023) |
| "Tranexamic acid (TXA) is poorly studied in patients with bone and musculoskeletal sarcoma due to perceived increased risk of venous thromboembolism (VTE)." | 4.31 | Intravenous tranexamic acid decreases intraoperative transfusion requirements and does not increase incidence of symptomatic venous thromboembolic events in musculoskeletal sarcoma surgery. ( Andrews, NA; Crowley, B; Hess, MC; Howie, C; McGwin, G; Siegel, H; Singh, NP, 2023) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug that has been shown to reduce blood loss following surgery." | 1.91 | Intravenous tranexamic acid is associated with an increased risk of pulmonary embolism following sarcoma resection. ( Foster, D; Garner, H; Goulding, K; Houdek, M; Sebro, R; Spaulding, AC; Stanborough, R; Wilke, B, 2023) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent used to reduce blood loss in orthopaedic procedures." | 1.56 | Tranexamic Acid in Patients With Cancer Undergoing Endoprosthetic Reconstruction: A Retrospective Review. ( Haase, DR; Rosenthal, HG; Sweeney, KR; Templeton, KJ, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (83.33) | 2.80 |
| Authors | Studies |
|---|---|
| Foster, D | 1 |
| Sebro, R | 1 |
| Garner, H | 1 |
| Stanborough, R | 1 |
| Spaulding, AC | 1 |
| Goulding, K | 1 |
| Houdek, M | 1 |
| Wilke, B | 1 |
| Sabharwal, S | 1 |
| LiBrizzi, CL | 1 |
| Forsberg, JA | 1 |
| Morris, CD | 1 |
| Levin, AS | 1 |
| Hess, MC | 1 |
| Andrews, NA | 1 |
| Crowley, B | 1 |
| Singh, NP | 1 |
| Howie, C | 1 |
| McGwin, G | 1 |
| Siegel, H | 1 |
| Haase, DR | 1 |
| Templeton, KJ | 1 |
| Rosenthal, HG | 1 |
| Sweeney, KR | 1 |
| Langhorn, R | 1 |
| Poulsen, MK | 1 |
| Heidemann, PL | 1 |
| Bochsen, L | 1 |
| Ritz, C | 1 |
| Kristensen, AT | 1 |
| Nielsen, LN | 1 |
| Sajdak, S | 1 |
| Moszynski, R | 1 |
| Opala, T | 1 |
1 trial available for tranexamic acid and Sarcoma
| Article | Year |
|---|---|
Incidence of and Risk Factors for Thromboembolism After Endoprosthetic Reconstruction in Musculoskeletal Oncology Patients.
Topics: Adult; Aged; Anticoagulants; Bone Diseases; Child; Humans; Incidence; Middle Aged; Prospective Studi | 2023 |
5 other studies available for tranexamic acid and Sarcoma
| Article | Year |
|---|---|
Intravenous tranexamic acid is associated with an increased risk of pulmonary embolism following sarcoma resection.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Postoperative Complications; Pulmonary Emboli | 2023 |
Intravenous tranexamic acid decreases intraoperative transfusion requirements and does not increase incidence of symptomatic venous thromboembolic events in musculoskeletal sarcoma surgery.
Topics: Adult; Humans; Incidence; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Tranexamic Acid; Ve | 2023 |
Tranexamic Acid in Patients With Cancer Undergoing Endoprosthetic Reconstruction: A Retrospective Review.
Topics: Antifibrinolytic Agents; Bone Neoplasms; Femur; Humans; Plastic Surgery Procedures; Postoperative He | 2020 |
Diagnosis of primary hyperfibrinolysis and in vitro investigation of the inhibitory effects of tranexamic acid in a group of dogs with sarcomas - A pilot study.
Topics: Animals; Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Coagulation Tests; Case-Control | 2021 |
Bleeding from endometrial and vaginal malignant tumors treated with activated recombinant factor VII.
Topics: Adenocarcinoma; Administration, Intravaginal; Adult; Aged; Endometrial Neoplasms; Ethamsylate; Facto | 2002 |